Magnetic Resources NL (ASX:MAU) Quarterly Report Highlights
Magnetic Resources NL reports significant drilling advancements at LJN4, with ongoing feasibility studies and encouraging gold recovery metrics.

Magnetic Resources NL reports significant drilling advancements at LJN4, with ongoing feasibility studies and encouraging gold recovery metrics.
Telix Pharmaceuticals reports a strong Q4 2024 performance, exceeding revenue guidance and advancing multiple therapeutic and imaging candidates.
Telix Pharmaceuticals (ASX: TLX) reports significant revenue growth and unveils strategic plans for multiple product launches in 2025.
Asian Battery Metals PLC reports high-grade mineralisation at the Oval project, indicating potential for continued exploration and development.
4DMedical Limited (ASX:4DX) secures a contract with the US DoD for its CT:VQ™ technology, aiming to enhance lung health assessments.
Althea Group Holdings (ASX:AGH) has secured a multiyear manufacturing agreement with The Boston Beer Company.
Imugene Limited (ASX:IMU) announces the receipt of an A$11.7m R&D tax refund to support its clinical development pipeline.
Challenger Gold Limited completes a $6.6M placement and secures a toll processing agreement ensuring operational checks for Hualilan project.
Arovella Therapeutics (ASX:ALA) announces a $20 million placement to fund Phase 1 clinical trials and solid tumour pipeline expansion.
Radiopharm raises A$8 million from Lantheus, increasing its shareholding to 12.16% to support the clinical pipeline.